RecruitingPhase 3NCT06714838

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Studying Chronic inflammatory demyelinating polyneuropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)
Intervention
Rituximab (Mabthera)(drug)
Enrollment
100 enrolled
Eligibility
18-80 years · All sexes
Timeline
20242028

Study locations (1)

Collaborators

Stichting Treatmeds · UMC Utrecht · Erasmus Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06714838 on ClinicalTrials.gov

Other trials for Chronic inflammatory demyelinating polyneuropathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic inflammatory demyelinating polyneuropathy

← Back to all trials